Skip to content

LBRX LBRX PP&E (Net)

PP&E (Net) at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$7.66B+6.2%
Alkermes logo
AlkermesALKS
$220.59M-5.7%
MapLight Therapeutics, Inc.
 logo
MapLight Therapeutics, Inc. MPLT
$968K
Alto Neuroscience logo
Alto NeuroscienceANRO
$2.23M-9.8%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$430K+1.9%
Opko Health logo
Opko HealthOPK
$72.59M+2.0%

Other financials

Income statement

See full
Net income-$19.1M-259%
EPS (diluted)-$0.67+95.5%

Balance sheet

See full
Cash & equivalents$320.7M
Total debt$3.5M
Total equity$378.7M+481%
Total assets$393.5M

Cash flow

See full
Operating cash flow-$23.3M-187%
CapEx$32.0K+52.4%
Free cash flow-$23.3M-186%

Valuation

See full
Market cap$874.06M+159%
Enterprise value$556.86M

Returns & leverage

See full
Return on equity-27.9%
Debt / equity
Current ratio35.7×

Where this comes from

Reported directly by LBRX in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: LBRX’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about LBRX's pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is LBRX's PP&E (net)?
LBRX (LBRX) reported PP&E (net) of $1.53M in Q1 2026.
What does PP&E (net) mean?
Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.